Annex II — Financial tender Financial Evaluation  Title:  Reference:  Lot 4:  Tenderer (name): Vaccine Effectiveness, Burden and Impact Studies of COVID-19 and Influenza OJ/2021/DPR/12924 Vaccine effectiveness and impact of COVID-19 vaccines through routinely collected exposure and outcome data using health registries The table below is automatically filled in from the first sheet. It is not editable. The scenario in the table is only meant for evaluation purposes and does not constitute a commitment on the part of ECDC to request this volume of services. The reference price below must not exceed the estimated maximum budget for this contract: € 6'300'000 Please print/upload BOTH SHEETS (Financial tender and Financial evaluation). Unit price at  coordination level Unit price at study  site level Expected  repetition(s) of  deliverable  Expected Number of  study sites  Total price (unit price x  scenario) € 0 4 € 0 € 0 40 € 0 € 0 4 € 0 € 0 16 € 0 € 0 2 € 0 € 0 8 € 0 € 0 1 € 0 € 0 3 € 0 € 0 2 € 0 € 0 4 € 0 € 0 2 € 0 € 0 2 € 0 € 0 1 10 € 0 € 0 8 € 0 € 0 96 10 € 0 € 0 16 € 0 € 0 4 € 0 € 0 6 € 0 € 0 16 € 0 € 0 8 € 0 € 0 4 € 0 € 0 4 € 0 DL 4.1.6 Reports on progress during each specific contract  Deliverables DL 4.1.1 Annual work plan for thelot, kick-off teleconferencewith ECDC and  minutes provided DL 4.1.2 Minutes of themonthly teleconferences between ECDC and the  contractor DL 4.3.4 Scientific materials for outputs on thecontent of thelot DL 4.4.1 Site-specific training/visit (In principleonly virtual trainings/ visits are  foreseen. If travel requested by ECDC costs will be reimbursed see contract  article I.5.3)  DL 4.4.2 Training workshops for study sites / information sharing workshop  DL 4.4.3 Report on capacity building DL 4.2.6 Country/sitespecific protocol and Standard Operating Procedures to  implement theEU/EEAprotocol. Priceincludesinitial investment in thesetting  up thestudy at country/sitelevel.  DL 4.2.7 Technical documents related to data collection such as reporting  protocol, metadata, and definitions. Priceof deliverablerefers to work  performed at coordination level for collection, data management, analysis of  DL 4.2.8 Validated datasets and production of regular epidemiological data  summary/report.  DL 4.3.1 Regular descriptiveand analytical report on results on vaccine  effectiveness DL 4.1.3 Onlineonlineannual meeting (approximately 60 participants) DL 4.1.4. Onlinetechnical meeting (approximately 30 participants) DL 4.1.5 Organisation of a faceto facemeeting, including meeting report DL 4.3.2 Annual descriptiveand analytical report DL 4.3.3 Draft manuscript inclusiveopen access publication fee DL 4.1.7 Report/Standard Operating Procedures to transfer knowledgegained  through theproject  DL 4.2.3 EU/EEA master protocol for a study on vaccineeffectiveness using  health registries DL 4.2.4 Proposed list of countries/sites joining thestudy  DL 4.2.5 Report describing all participating countries/study sites, with standard  templateacross sites DL 4.2.1 Feasibility/landscapeanalysis and report DL 4.2.2 Pilot protocol and pilot study. Theprotocol and associated study  documents will bepilot tested in a minimum of 2 countries/study sites for a  period of maximum 3 months Page 11 of 15